Semaglutide

Study	Type of data	Exposure measurement	Outcome assessment	Adjustment
Kolding (Controls exposed to insulin), 2025	retrospective cohort	Exposure to semaglutide (ATC A10BJ06) and/or insulin (ATC A10B) in first trimester (from the estimated conception date to 70 days after, corresponding to GA 12 0/7), pregnancy and neonatal outcomes and informations regarding diabetes were collected from the electronic patient record.	Data were collected from the electronic charts from all hospitals in the region.	Singletons only. No adjustment.
Kolding (Controls unexposed, general pop), 2025	retrospective cohort	Exposure to semaglutide (ATC A10BJ06) and/or insulin (ATC A10B) in first trimester (from the estimated conception date to 70 days after, corresponding to GA 12 0/7), pregnancy and neonatal outcomes and informations regarding diabetes were collected from the electronic patient record.	Data were collected from the electronic charts from all hospitals in the region.	Singletons only. No adjustment.
Maya, 2025	retrospective cohort	Maternal medications were obtained in the electronic health record (EHR) from the Mass General Brigham Enterprise Data Warehouse and the Mass General Brigham Research. The exposed and unexposed classifications were validated through manual medical record review of a subset of exposed participants.	Maternal anthropometric and delivery data were obtained from the Mass General Brigham Enterprise Data Warehouse; additional maternal diagnostics were obtained from the Mass General Brigham Research. Prepregnancy weight was self-reported and documented in the electronic health record (EHR).	Singleton only. Propensity score (and/or adjusted): body mass index, maternal age, parity, race and ethnicity, insurance type, preexisting diabetes (except for gestational diabetes analysis because this group was excluded), preexisting chronic hypertension (except for hypertensive disorders of pregnancy analysis because this group was excluded), year of delivery, and delivery location.

master protocol